ST elevation myocardial infarction thienopyridine therapy: Difference between revisions

Jump to navigation Jump to search
Line 6: Line 6:


==Overview==
==Overview==
There are at present two agents available in this class, [[Ticlopidine]] and [[clopidogrel]]. [[Prasugrel]] is currently an investigational drug in this class. These agents inhibit the [[ADP]]-receptor and thereby reduce [[platelet activation]].  As an adjunct to [[fibrinolytic therapy]], [[clopidogrel]] has been associated with improved patency in the CLARITY trial (300 mg loading dose and 75 mg/day maintenance dose), and a reduction in mortality in the COMMIT trial (75 mg/day loading and maintenance dose). Among [[STEMI]] patients treated with a [[fibrinolytic agent]], co-administration of [[clopidogrel]] at a loading dose of 300 mg and a maintenance dose of 75 mg/day should be viewed as the standard of care.
Antiplatelet therapy is a mainstay of pharmacotherapy in STEMI. In the International Study of Infarct Survival 2 (ISIS 2), [[aspirin]] reduced mortality in [[STEMI]] as much as [[streptokinase]] over the administration of neither agent, by approximately 42%. <ref name="pmid2903874">{{cite journal |author= |title=Randomized trial of intravenous streptokinase, oral aspirin, both, or neither among 17,187 cases of suspected acute myocardial infarction: ISIS-2.ISIS-2 (Second International Study of Infarct Survival) Collaborative Group |journal=J. Am. Coll. Cardiol. |volume=12 |issue=6 Suppl A |pages=3A–13A |year=1988 |month=December |pmid=2903874 |doi= |url=}}</ref>
 
Thienopyridines inhibit [[ADP]] mediated [[platelet activation]] and have been found to further improve outcomes of STEMI patients treated with a [[fibrinolytic agent]] for [[STEMI]]. There are at present two agents available in this class, [[Ticlopidine]] and [[clopidogrel]]. [[Prasugrel]] is currently an investigational drug in this class. These agents inhibit the [[ADP]]-receptor and thereby reduce [[platelet activation]].  As an adjunct to [[fibrinolytic therapy]], [[clopidogrel]] has been associated with improved patency in the CLARITY trial (300 mg loading dose and 75 mg/day maintenance dose), and a reduction in mortality in the COMMIT trial (75 mg/day loading and maintenance dose). Among [[STEMI]] patients treated with a [[fibrinolytic agent]], co-administration of [[clopidogrel]] at a loading dose of 300 mg and a maintenance dose of 75 mg/day should be viewed as the standard of care.


==Angiographic efficacy of Clopidogrel as adjunctive therapy to fibrinolysis in STEMI patients==
==Angiographic efficacy of Clopidogrel as adjunctive therapy to fibrinolysis in STEMI patients==

Revision as of 21:19, 15 February 2009

WikiDoc Resources for ST elevation myocardial infarction thienopyridine therapy

Articles

Most recent articles on ST elevation myocardial infarction thienopyridine therapy

Most cited articles on ST elevation myocardial infarction thienopyridine therapy

Review articles on ST elevation myocardial infarction thienopyridine therapy

Articles on ST elevation myocardial infarction thienopyridine therapy in N Eng J Med, Lancet, BMJ

Media

Powerpoint slides on ST elevation myocardial infarction thienopyridine therapy

Images of ST elevation myocardial infarction thienopyridine therapy

Photos of ST elevation myocardial infarction thienopyridine therapy

Podcasts & MP3s on ST elevation myocardial infarction thienopyridine therapy

Videos on ST elevation myocardial infarction thienopyridine therapy

Evidence Based Medicine

Cochrane Collaboration on ST elevation myocardial infarction thienopyridine therapy

Bandolier on ST elevation myocardial infarction thienopyridine therapy

TRIP on ST elevation myocardial infarction thienopyridine therapy

Clinical Trials

Ongoing Trials on ST elevation myocardial infarction thienopyridine therapy at Clinical Trials.gov

Trial results on ST elevation myocardial infarction thienopyridine therapy

Clinical Trials on ST elevation myocardial infarction thienopyridine therapy at Google

Guidelines / Policies / Govt

US National Guidelines Clearinghouse on ST elevation myocardial infarction thienopyridine therapy

NICE Guidance on ST elevation myocardial infarction thienopyridine therapy

NHS PRODIGY Guidance

FDA on ST elevation myocardial infarction thienopyridine therapy

CDC on ST elevation myocardial infarction thienopyridine therapy

Books

Books on ST elevation myocardial infarction thienopyridine therapy

News

ST elevation myocardial infarction thienopyridine therapy in the news

Be alerted to news on ST elevation myocardial infarction thienopyridine therapy

News trends on ST elevation myocardial infarction thienopyridine therapy

Commentary

Blogs on ST elevation myocardial infarction thienopyridine therapy

Definitions

Definitions of ST elevation myocardial infarction thienopyridine therapy

Patient Resources / Community

Patient resources on ST elevation myocardial infarction thienopyridine therapy

Discussion groups on ST elevation myocardial infarction thienopyridine therapy

Patient Handouts on ST elevation myocardial infarction thienopyridine therapy

Directions to Hospitals Treating ST elevation myocardial infarction thienopyridine therapy

Risk calculators and risk factors for ST elevation myocardial infarction thienopyridine therapy

Healthcare Provider Resources

Symptoms of ST elevation myocardial infarction thienopyridine therapy

Causes & Risk Factors for ST elevation myocardial infarction thienopyridine therapy

Diagnostic studies for ST elevation myocardial infarction thienopyridine therapy

Treatment of ST elevation myocardial infarction thienopyridine therapy

Continuing Medical Education (CME)

CME Programs on ST elevation myocardial infarction thienopyridine therapy

International

ST elevation myocardial infarction thienopyridine therapy en Espanol

ST elevation myocardial infarction thienopyridine therapy en Francais

Business

ST elevation myocardial infarction thienopyridine therapy in the Marketplace

Patents on ST elevation myocardial infarction thienopyridine therapy

Experimental / Informatics

List of terms related to ST elevation myocardial infarction thienopyridine therapy

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]

Please Take Over This Page and Apply to be Editor-In-Chief for this topic: There can be one or more than one Editor-In-Chief. You may also apply to be an Associate Editor-In-Chief of one of the subtopics below. Please mail us [2] to indicate your interest in serving either as an Editor-In-Chief of the entire topic or as an Associate Editor-In-Chief for a subtopic. Please be sure to attach your CV and or biographical sketch.

Overview

Antiplatelet therapy is a mainstay of pharmacotherapy in STEMI. In the International Study of Infarct Survival 2 (ISIS 2), aspirin reduced mortality in STEMI as much as streptokinase over the administration of neither agent, by approximately 42%. [1]

Thienopyridines inhibit ADP mediated platelet activation and have been found to further improve outcomes of STEMI patients treated with a fibrinolytic agent for STEMI. There are at present two agents available in this class, Ticlopidine and clopidogrel. Prasugrel is currently an investigational drug in this class. These agents inhibit the ADP-receptor and thereby reduce platelet activation. As an adjunct to fibrinolytic therapy, clopidogrel has been associated with improved patency in the CLARITY trial (300 mg loading dose and 75 mg/day maintenance dose), and a reduction in mortality in the COMMIT trial (75 mg/day loading and maintenance dose). Among STEMI patients treated with a fibrinolytic agent, co-administration of clopidogrel at a loading dose of 300 mg and a maintenance dose of 75 mg/day should be viewed as the standard of care.

Angiographic efficacy of Clopidogrel as adjunctive therapy to fibrinolysis in STEMI patients

The angiographic effectiveness of clopidogrel as adjunctive therapy to fibrinolytic administration was evaluated in the Clopidogrel as Adjunctive Reperfusion Therapy (CLARITY)-TIMI 28 trial. [2] [3] [4] This study randomized 3,491 STEMI patients to treatement with either placebo or a 300 mg loading dose of clopidogrel followed by a maintenance dose of 75 mg/day. The trial demonstrated a 35% relative risk reduction in the incidence of an occluded artery on angiography, death, or MI associated with clopidogrel administration. [2]

Safety of Clopidogrel in CLARITY

Clopidogrel administration was not associated with an increase in TIMI major bleeding or intracranial hemorrhage (ICH). Indeed, the incidence of all causes of stroke was reduced by 46% (P = 0.052).

Generalizability of results from CLARITY

There was no heterogeneity in the treatment benefit (that is a consistent benefit was observed) irrespective of:

  1. Type of fibrinolytic (2/3rds of patients were treated with a fibrin-specific agent such as tPA, rPA, nPA, or TNK) or
  2. Tyep of antithrombin administered (45.8% received UFH, 29.6% received enoxaparin, 24.5% received both or none).

It is important to note that the following patient groups were excluded from participation in CLARITY, and the results of CLARITY are not applicable to these subgroups: patients over 75 years of age, those with creatinine > 2.5 mg/dL, patients with cardiogenic shock, or patients who had previously undergone coronary artery bypass grafting (CABG). It should also be noted that the rate of PCI or CABG was high at 63%. This may be due to the fact protocol-mandated angiography was performed in countries with a high rate of adjunctive PCI such as Europe and the United States.

Reduction in mortality associated with clopidogrel administration in conjunction with fibrinolytic agents: Results of COMMIT

The COMMIT (ClOpidogrel and Metoprolol in Myocardial Infarction Trial) collaborative group evaluated the safety and efficacy of clopidogrel as an adjunct to fibrinolytic therapy in 45,852 patients at 1250 Chinese hospitals who presented in the first 24 hours of STEMI (93% had ST segment elevation or left bundle branch block, the rest had ST segment depression). [5] As adjunctive therapy to 162 mg of aspirin daily, patients were randomized to clopidogrel 75 mg daily without a 300 mg loading dose which continued until discharge or up to 4 weeks in hospital (mean 15 days in survivors)(n=22,961) or placebo (n=22,891). Clopidogrel administration was associated with a 9% relative reduction (95% CI 3-14) in the co-primary endpoint of death, reinfarction, or stroke (2121 [9.2%] clopidogrel vs 2310 [10.1%] placebo; p=0.002). This would translate into to nine fewer deaths, re MIs or strokes per 1000 patients treated for two weeks. Likewise, there was a 7% relative risk reduction (95% CI 1-13) in all cause death (1726 [7.5%] vs 1845 [8.1%]; p=0.03). The benefits were consistent across a broad range of subgroups, antithrombins and fibrinolytic agents.

With respect to safety, there was no excess of fatal stroke or intracranial hemmorhage associated with clopidogrel administration, either in patients of all ages (134 [0.58%] vs 125 [0.55%]; p=0.59), or among patients who were over 70 years of age.

Dosing of clopidogrel in STEMI

Fibrinolytic therapy patients

Data from the non-ST elevation MI population does demonstrate that a 600 mg oral dose achieves sustained inhibition more rapidly than a 300 mg dose. A 600 mg dose does not, however, achieve a higher level of inhibition. The FDA package insert loading dose is 300 mg, but in clinical practice both 300 and 600 mg doses are used. A loading dose of 600 mg of clopidogrel has not been studied in conjunction with fibrinolytic therapy and cannot be recommended.

Primary PCI patients

The optimal loading dose in patients with STEMI undergoing primary PCI has not been rigorously evaluated in randomized trials. The ARMYDA 2 trial evaluated the efficacy of 300 mg vs 600 mg of clopidogrel before elective PCI, and the benefits observed in this trial (a reduction in the risk of death, MI or target vessel revascularization from 12% to 4%, p=0.041) may not be applicable to the STEMI population. [6] In the HORIZONS AMI trial, a loading dose of 600 vs 300 mg of clopidogrel was associated with a lower rate of death (3.1% vs 1.9%, p=0.03) as well as reinfarction (2.4% vs 1.3%, p=0.02) and a trend toward lower rates of stroke (1.0% vs 0.4%, p=0.058). There was no difference in pre-PCI flow between the two strategies. An important confounder was the fact that 7.5% of patients treated with a 600 mg loading dose received a GP IIbIIIa inhibitor in the emergency room compared to only 3.2% of those treated with a 300 mg loading dose (p<0.0001). There were also large and significant imbalances in Killip class, femoral access, closure device use, and peak ACT between the two loading doses (all p<0.0001). Given the non randomized nature of this analysis, and the potential confounders, no firm conclusions can be made regarding the optimal loading dose of clopidogrel before primary PCI from this analysis.

Side effects of thienopyridines

Ticlopidine administration has been associated with neutropenia and thrombotic thrombocytopenia (TTP). It is as a result of these potential side effects that clopidogrel is often prescribed instead. Clopidogrel may also be preferred because of the lack of need for laboratory monitoring, and once-daily dosing. It should be noted, however, that approximately one third to one quarter of patients may be resistant to clopidogrel, which is a pro-drug. For those patients who develop stent thrombosis while on clopidogrel, ticlopidine may be an optimal substitution because it is not a pro-drug and is not metabolized by the same pathway as clopidogrel.

ACC / AHA Guidelines (DO NOT EDIT)

  • Class I

1. In patients who have undergone diagnostic cardiac catheterization and for whom PCI is planned, clopidogrel should be started and continued for at least 1 month after bare metal stent implantation, for several months after drug-eluting stent implantation (3 months for sirolimus, 6 months for paclitaxel), and up to 12 months in patients who are not at high risk for bleeding. (Level of Evidence: B)

2. In patients taking clopidogrel in whom CABG is planned, the drug should be withheld for at least 5 days, and preferably for 7 days, unless the urgency for revascularization outweighs the risks of excess bleeding. (Level of Evidence: B)

  • Class IIa

Clopidogrel is probably indicated in patients receiving fibrinolytic therapy who are unable to take aspirin because of hypersensitivity or major gastrointestinal intolerance. (Level of Evidence: C)

References

  1. "Randomized trial of intravenous streptokinase, oral aspirin, both, or neither among 17,187 cases of suspected acute myocardial infarction: ISIS-2.ISIS-2 (Second International Study of Infarct Survival) Collaborative Group". J. Am. Coll. Cardiol. 12 (6 Suppl A): 3A–13A. 1988. PMID 2903874. Unknown parameter |month= ignored (help)
  2. 2.0 2.1 Sabatine MS, Cannon CP, Gibson CM; et al. (2005). "Addition of clopidogrel to aspirin and fibrinolytic therapy for myocardial infarction with ST-segment elevation". N. Engl. J. Med. 352 (12): 1179–89. doi:10.1056/NEJMoa050522. PMID 15758000. Unknown parameter |month= ignored (help)
  3. Sabatine MS, Morrow DA, Montalescot G; et al. (2005). "Angiographic and clinical outcomes in patients receiving low-molecular-weight heparin versus unfractionated heparin in ST-elevation myocardial infarction treated with fibrinolytics in the CLARITY-TIMI 28 Trial". Circulation. 112 (25): 3846–54. doi:10.1161/CIRCULATIONAHA.105.595397. PMID 16291601. Unknown parameter |month= ignored (help)
  4. Gibson CM, Murphy SA, Pride YB; et al. (2008). "Effects of pretreatment with clopidogrel on nonemergent percutaneous coronary intervention after fibrinolytic administration for ST-segment elevation myocardial infarction: a Clopidogrel as Adjunctive Reperfusion Therapy-Thrombolysis in Myocardial Infarction (CLARITY-TIMI) 28 study". Am. Heart J. 155 (1): 133–9. doi:10.1016/j.ahj.2007.08.034. PMID 18082504. Unknown parameter |month= ignored (help)
  5. Chen ZM, Jiang LX, Chen YP; et al. (2005). "Addition of clopidogrel to aspirin in 45,852 patients with acute myocardial infarction: randomised placebo-controlled trial". Lancet. 366 (9497): 1607–21. doi:10.1016/S0140-6736(05)67660-X. PMID 16271642. Unknown parameter |month= ignored (help)
  6. Patti G, Chello M, Candura D; et al. (2006). "Randomized trial of atorvastatin for reduction of postoperative atrial fibrillation in patients undergoing cardiac surgery: results of the ARMYDA-3 (Atorvastatin for Reduction of MYocardial Dysrhythmia After cardiac surgery) study". Circulation. 114 (14): 1455–61. doi:10.1161/CIRCULATIONAHA.106.621763. PMID 17000910. Unknown parameter |month= ignored (help)

Template:WH Template:WikiDoc Sources